Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Express News | Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report